A5067701944- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Head and Neck Cancer Studies
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
The University of Texas MD Anderson Cancer Center
2022-2024
Background The correlation between elevated T-cell infiltration and improved survival of ovarian cancer (OvCa) patients suggests that endogenous tumor-infiltrating lymphocytes (TIL) possess some degree antitumor activity can be harnessed for OvCa immunotherapy. We previously optimized a protocol ex vivo TIL expansion adoptive cell therapy, which is now being tested in clinical trial at our institution ( NCT03610490 ). Building on this success, we embarked genetic modification to overcome key...
6059 Background: CIAO (Checkpoint Inhibitors Assessment in Oropharynx cancer) was a window of opportunity trial evaluating the anti-PD-L1 durvalumab (durva) with or without anti-CTLA-4 tremelimumab (treme) prior to surgery 28 oropharynx squamous cell carcinoma (OPC) patients (pts). Here we report correlative analyses and long-term survival outcomes. Methods: A total OPC pts were randomized receive durva (n=14) plus treme for 2 cycles surgery. Adjuvant radiotherapy concomitant chemotherapy...